Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Ocrelizumab in Patients With Radiologically Isolated Syndrome

NCT04877457 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04877457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04877457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Ocrelizumab in Patients With Radiologically Isolated Syndrome
Lead sponsor
Yale University
Phase
Phase 4
Overall status
Terminated
Start date
February 15, 2022
Completion date
June 12, 2023
Enrollment
3 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, radiologically isolated syndrome